The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects

Drug Interaction Clinical Trial

Official title:

A Phase 4, Single-center, Open-label, Parallel Study to Evaluate the Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04006353
• Other study ID #: FB-ABWT-401
• Status: Completed
• Phase: Phase 4
• Start date: July 11, 2019
• Est. completion date: December 3, 2019

Study information

• Verified date: September 2021
• Source: Shanghai Public Health Clinical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to estimate the drug interaction between RIF and ABT. This will be a single-center, open-label, parallel study in healthy adult subjects.

Description:

The purpose of this study is to describe and compare RIF and ABT pharmacokinetics following administration of 320mg ABT and 600mg RIF.12 subjects will receive 320mg ABT on Days 1、2、3、8 (Treatment 1). And 12 subjects will receive 600mg RIF daily for 16 days from Day 1 to 16, and receive 320mg ABT on Days 7、8、9 and 14 (Treatment 2).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 3, 2019
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females, age between 18 and 65 years;

• Healthy as determined by a responsible and experienced physician, based on a medical evaluation including physical examination, laboratory tests, Chest X-ray, abdominal B-ultrasound and ECG; No serious liver and kidney dysfunction, normal albumin value, and other indicators are in the normal range;

• Subjects weighing =50 kg and their BMI within the range 18.5-27.0 kg/m^2 (inclusive);

• Agrees not to consume alcohol during the study;

• Both male and female subjects and their partners of childbearing potential agree to use contraception during the study;

• Females of childbearing potential must have a negative serum pregnancy test at Screening visit prior to receiving the first dose of study drug;

• ALT?AST?ALP and TBIL=1×ULN;

• Willing and able to participate in all aspects of the study, including use of intravenous medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion Criteria:

• A positive anti-HIV-1 antibody result;

• A positive pre-study Hepatitis B surface antigen result;

• A Positive Hepatitis C antibody result;

• Syphilis infection as manifest by positive RPR;

• History of tuberculosis (TB) or lung disease;

• Currently active severe chronic diseases, metabolic diseases (such as diabetes), cardiovascular diseases, neurological and psychiatric diseases;

• Any known allergy or antibodies to the study drug or rifampicin;

• Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study;

• Active alcohol or drug abuse;

• Participation in an experimental drug trial(s) within 30 days or 5 half-lives of the Screening Visit;

• Currently active or chronic gastrointestinal dysfunction, or liver and kidney function disorders, would affect the absorption, metabolism, and/or excretion of the study drug. Subjects with a history of cholecystectomy, pepticulcer, inflammatory bowel disease or pancreatitis should be excluded;

• Use other prescription or over-the-counter medications, including vitamins, herbal medicines, or dietary supplements, 7 days prior to dosing or 5 half-life, unless the investigator believes that the drug will not interfere with the study procedure or compromise the safety of the subject;

• Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Related Conditions & MeSH terms

• Drug Interaction

Intervention

Drug:
• ABT
320 mg, Intravenous infusion
• RIF
600mg q.d.

Locations

Country	Name	City	State
China	Shanghai Public Health Clinical Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Public Health Clinical Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Plasma Concentration (Cmax) of ABT following ABT 320mg administration with and without RIF 600mg qd	Pharmacokinetic(PK) parameters	Up to 17 days
Primary	Peak Plasma Concentration (Cmax) of RIF 600mg qd administration with and without ABT 320mg	PK parameters	Up to 17 days
Primary	Area under the plasma concentration versus time curve (AUC) of ABT following ABT 320mg administration with and without RIF 600mg qd	PK parameters	Up to 17 days
Primary	Area under the plasma concentration versus time curve (AUC) of RIF 600mg qd administration with and without ABT 320mg	PK parameters	Up to 17 days
Secondary	Number of subjects with abnormal findings for laboratory parameters	Number of subjects with Grade 3/4 laboratory parameters	Up to 17 days
Secondary	Number of subjects with adverse events.	An adverse event is any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.	Up to 17 days
Secondary	Number of subjects with severity of adverse events	The Division of AIDS table for grading the severity of adult and pediatric adverse events will be used to assess severity.	Up to 17 days